Form D · Hedge Fund
Zakara Biotechnology Fund LP
New York, NY · CIK 0002058789
Offering snapshot reported Apr 22, 2026 · SEC filing
- Reported sold
- $15K Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 1, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 1
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 22, 2026 | Amendment | $15,000 | No comparison | 1 | SEC filing |
| Apr 15, 2025 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Pooled investment fund
- Exemptions
- 06b, 3C, 3C.7
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-543714
Source: Form D, filed Apr 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Janet Okogbaa | Executive, Promoter |
| Zakara Biotechnology Fund Gp Llc | Executive, Promoter |
| Zakara Capital Llc | Executive, Promoter |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
300 Park Avenue 2 Nd Floor, Suite 201
New York, NY, 10022
New York, NY, 10022